Vertaling van "potential risk " (Nederlands → Frans) :

TERMINOLOGIE

afwijkend(e) | elektro-oculogram [EOG] | afwijkend(e) | elektromyogram [EMG] | afwijkend(e) | elektroretinogram [ERG] | afwijkend(e) | respons op zenuwstimulatie | afwijkend(e) | visually evoked potential [VEP]
Anomalies (de):électromyogramme [EMG] | électro-oculogramme [EOG] | électrorétinogramme [ERG] | potentiels évoqués visuellement | réponse à une stimulation nerveuse

potentiëring | versterking
potentiation/potentialisation | augmentation de l'action d'un médicament par l'absorption d'un second

potentie | kracht
1) puissance sexuelle - 2) efficacité | 1) puissance sexuelle - 2) d'un médicament

controle van zwangerschap met verhoogd risico [high-risk]
Surveillance d'une grossesse à haut risque

IN-CONTEXT TRANSLATIONS

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

However, the Council remains concerned that these energy drinks increase the risk of excessive and potentially harmful caffeine consumption and its consequences (such as insomnia, nervousness, anxiety, headaches, trembling and tachycardia), as well as the risk of potentially inducing an addiction to caffeine and, as has been noted more recently, a dependence on other substances (nicotine, alcohol and/or cannabis).
Il reste néanmoins préoccupé par le risque accru d’une surconsommation potentiellement nuisible de caféine et des conséquences que celle-ci implique telles que insomnie, nervosité, anxiété, maux de tête, tremblements et tachycardie, mais également, la possibilité d’induction d’une dépendance à la caféine ou à d’autres substances (nicotine, alcool et/ou cannabis), plus récemment évoquée.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines.
DISCLOSURE NOTICE: The information contained in this release is as of December 12, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

concerned about the increased risk of potentially harmful caffeine-abuse and all its consequences (such as insomnia, nervousness, anxiety, headache, trembling and tachycardia), as well as the fact that these beverages may induce an addiction to caffeine or, as has been discovered more recently, a dependence on other substances (nicotine, alcohol and/or cannabis).
En conséquence, le Conseil Supérieur de la Santé prend acte de la mise à disposition de données rassurantes sur l’innocuité de deux principaux composants des boissons énergisantes, à savoir la taurine et la D-glucuronolactone, mais reste préoccupé par le risque accru qu’elles entraînent d’une surconsommation potentiellement nuisible de caféine, avec les conséquences que celle-ci implique telles que insomnie, nervosité, anxiété, maux de tête, tremblements et tachycardie, mais également, la possibilité d’induction d’une dépendance à la caféine ou à d’autres substances (nicotine, alcool et/ou cannabis), plus récemment évoquée.

In the above-mentioned recent advisory report of the German Federal Institute for Risk Assessment (BfR, 2008) concerning energy drinks and caffeine in particular, there was an explicit re-evaluation of the potential consequences of consuming beverages containing up to 320 mg/litre of caffeine, 4 000 mg/litre of taurine and 2 400 mg/litre of D-glucuronolactone. It continues to express its reservations on this subject and makes the following recommendations:
Par rapport aux boissons énergisantes et à la caféine en particulier, l’avis récent de l’Institut fédéral allemand d’évaluation des risques (BfR, 2008), évoqué plus haut, indique avoir explicitement réévalué les risques potentiels consécutifs à l’ingestion de boissons contenant au maximum 320 mg/l de caféine, 4.000 mg/l de taurine et 2.400 mg/l de D-glucuronolactone et continue à manifester des réserves à leur égard tout en émettant les recommandations suivantes:

Moreover, these groups are rarely homogenous, which in turn means that they cannot be referred to in general terms (e.g. as regards immigrants: it is certainly not the fact that one is an “immigrant” that puts one at risk of depression or suicide. Instead, this may be the consequence of broken social ties, which are a potential outcome of this type of situation).
Par ailleurs, ces groupes sont rarement homogènes et on ne peut dès lors pas en parler en termes de généralités (exemple: les allochtones; ce n’est certainement pas le fait « d’être allochtone » qui peut comporter des risques de dépression ou de suicide mais bien la rupture du lien social que peut, éventuellement, entraîner ce type de situation).